Devansu Tewari
Gynecologic Oncology · Anaheim, CANPI 1902827835
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,500 of the $3,398 with a category attached, or 73.6%. Menarini Silicon Biosystems, Inc. accounts for 76.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $2,735 and has fallen 92.2% since, to $212 in 2025.
Across 12 payments — averaging $283.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Menarini Silicon Biosystems, Inc.$3K
- GSK$236
- Pfizer$136
- Myriad Genetic Laboratories, Inc.$125
- AstraZeneca$122
- Genmab U.S., Inc.$117
- plus $63 from 2 others
Across 46 payments — averaging $12,946 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$378K
- AbbVie$116K
- Genmab U.S., Inc.$102K
What the payments were for
- Speaking & faculty fees$2,50074%
- Food & beverage$89826%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Menarini Silicon Biosystems, Inc. | 2 | $2,600 |
| GSK | 4 | $236 |
| Pfizer | 1 | $136 |
| Myriad Genetic Laboratories, Inc. | 1 | $125 |
| AstraZeneca | 1 | $122 |
| Genmab U.S., Inc. | 1 | $117 |
| Eisai Inc. | 1 | $36 |
| Intuitive Surgical | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CELLSEARCH$2,500
- TIVDAK$252
- myChoice CDx$125
- LYNPARZA$122
How this compares
$3,398 in reported general payments places this provider in the 60th percentile of 152 gynecologic oncology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 18 | $245,665 |
| Everolimus | 11 | $4,373 |
| Megestrol Acetate | 20 | $1,073 |
| Nystatin | 16 | $558 |
| Tamoxifen Citrate | 23 | $432 |
| Ibuprofen | 24 | $224 |
| Dexamethasone | 13 | $189 |
| Ondansetron Hcl | 20 | $161 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLynparza | $122 | $245,66518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 152 gynecologic oncology providers in California.
Other gynecologic oncology in Anaheim
- John ChanSan Francisco$2M
- Dana ChaseLos Angeles$1.3M
- Ramez EskanderEncinitas$706K
- Krishnansu TewariOrange$495K
- Fabio CappucciniOrange$313K
- Mehdi Moslemi-KebriaUpland$225K
- Amer KaramStanford$168K
- Rebecca BrooksSacramento$133K
- Kenneth KimWest Hollywood$88K
- Oliver DorigoStanford$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.